146 related articles for article (PubMed ID: 38078840)
21. Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
Quang C; Chung AW; Frazer IH; Toh ZQ; Licciardi PV
Trends Immunol; 2022 Oct; 43(10):815-825. PubMed ID: 35995705
[TBL] [Abstract][Full Text] [Related]
22. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
[TBL] [Abstract][Full Text] [Related]
23. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
24. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K; Kemp TJ; Kreimer AR; Basu P; Changalucha J; Hildesheim A; Porras C; Whitworth H; Herrero R; Lacey CJ; Schiller JT; Lucas E; Mutani P; Dillner J; Indangasi J; Muwonge R; Hayes RJ; Pinto LA; Watson-Jones D
Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
26. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
27. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
[TBL] [Abstract][Full Text] [Related]
28. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
Donkoh ET; Dassah ET; Owusu-Dabo E
BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
[TBL] [Abstract][Full Text] [Related]
29. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
30. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
31. Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India.
Bhatla N; Nene BM; Joshi S; Esmy PO; Poli URR; Joshi G; Verma Y; Zomawia E; Pimple S; Prabhu PR; Basu P; Muwonge R; Hingmire S; Sauvaget C; Lucas E; Pawlita M; Gheit T; Jayant K; Malvi SG; Siddiqi M; Michel A; Butt J; Sankaran S; Kannan TPRA; Varghese R; Divate U; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Kriplani A; Mishra G; Jadhav R; Thorat R; Tommasino M; Pillai MR; Sankaranarayanan R;
Papillomavirus Res; 2018 Jun; 5():163-171. PubMed ID: 29578097
[TBL] [Abstract][Full Text] [Related]
32. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
Schwarz TF; Galaj A; Spaczynski M; Wysocki J; Kaufmann AM; Poncelet S; Suryakiran PV; Folschweiller N; Thomas F; Lin L; Struyf F
Cancer Med; 2017 Nov; 6(11):2723-2731. PubMed ID: 28984053
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
34. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.
Barnabas RV; Brown ER; Onono M; Bukusi EA; Njoroge B; Winer RL; Donnell D; Galloway D; Cherne S; Heller K; Leingang H; Morrison S; Rechkina E; McClelland RS; Baeten JM; Celum C; Mugo N;
Trials; 2021 Sep; 22(1):661. PubMed ID: 34579786
[TBL] [Abstract][Full Text] [Related]
35. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Watson-Jones D; Changalucha J; Whitworth H; Pinto L; Mutani P; Indangasi J; Kemp T; Hashim R; Kamala B; Wiggins R; Songoro T; Connor N; Mbwanji G; Pavon MA; Lowe B; Mmbando D; Kapiga S; Mayaud P; de SanJosé S; Dillner J; Hayes RJ; Lacey CJ; Baisley K
Lancet Glob Health; 2022 Oct; 10(10):e1473-e1484. PubMed ID: 36113531
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
39. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
40. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
